medigraphic.com
ISSN 1560-4381 (Print)

2019, Number 4

<< Back Next >>

Correo Científico Médico 2019; 23 (4)

Dyslipidemia in insulin resistance states

Feria DGE, Leyva PCA, Rodríguez RER, Rodríguez MY, Rodríguez DR

Language: Spanish
References: 39
Page:
PDF size: 435.74 Kb.


ABSTRACT

Dyslipidemia associated with insulin resistance is a common condition that increases the risk of atherosclerosis and diabetes mellitus. This bibliographic review describes the prevalence, categories and etiology of dyslipidemias; also the main alterations that occur in lipoproteins and their impact in blood lipid concentrations as well as the relationship between liver steatosis and inflammation. Finally, the therapeutic procedure for dyslipidemias is described through lifestyle modifications (hypocaloric diets, physical exercises, smoking cessation, reduction of alcohol consumption) and the use of lipidemia reducing medications such as statins, ezetimibe, fibrates, monoclonal antibodies, bile acid sequestrants, niacin and omega-3 fatty acids.


REFERENCES

  1. Arsentales Montalva V, Tenorio Guadalupe M, Bernabé Ortiz A. Asociación entre actividad física ocupacional y síndrome metabólico: Un estudio poblacional en Perú. Rev Chilena Nutr. 2019 [citado 6 sep 2019]; 46(4): 392-399. Disponible en: http://dx.doi.org/10.4067/S0717-75182019000400392

  2. Silva Oliveira J, Silva de Oliveira Boery RN. Associação de variantes polimórficas com síndrome metabólica: uma revisão integrative. J Vasc Bras. 2018 [citado 6 sep 2019];17( 2 ): 141-147. Disponible en: http://dx.doi.org/10.1590/1677-5449.007917

  3. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018[citado 7 sep 2019]; 17(1): 122. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119242/pdf/12933_2018_Article_762.pdf

  4. Carballo Ramos EV, Miguel Soca PE. Trastornos metabólicos en la obesidad abdominal. Rev Habanera Cienc Méd. 2018 [citado 6 sep 2019]; 17(6): 1005-1008. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2018000601005&lng=es

  5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001[citado 6 sep 2019]; 285(19):2486-2497. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/193847

  6. Lian Y, Xie L, Liu Y, Tang F. Metabolic-related markers and inflammatory factors as predictors of dyslipidemia among urban Han Chinese adults. Lipids Health Dis. 2019[citado 6 sep 2019]; 18(1):167. Disponible en: https://lipidworld.biomedcentral.com/articles/10.1186/s12944-019-1109-1

  7. González Rivas JP, Nieto Martínez R, Brajkovich I, Ugel E, Rísquez A. Prevalence of Dyslipidemias in Three Regions in Venezuela: The VEMSOLS Study Results. Arq Bras Cardiol. 2018 [citado 6 sep 2019]; 110(1): 30–35. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831299/pdf/abc-110-01-0030.pdf

  8. Miguel Soca P, Sarmiento Teruel Y, Mariño Soler AL, Llorente Columbié Y, Rodríguez Graña T, Peña González M. Prevalencia de enfermedades crónicas no transmisibles y factores de riesgo en adultos mayores de Holguín. Rev Finlay. 2017 [citado 7 sep 2019]; 7(3): 155-167. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342017000300002&lng=es

  9. Pérez Berlanga AM, Hernández Pifferrer G, Rodríguez Diéguez M. Determinaciones de laboratorio clínico en pacientes obesos y su relación con el síndrome metabólico. CCM. 2017 [citado 6 sep 2019];21(3). Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/2567

  10. Miguel Soca PE, Rivas Estévez M, Sarmiento Teruel Y, Mariño Soler AL, Marrero Hidalgo M, Mosqueda Batista L, et al. Prevalence of Metabolic Syndrome Risk Factors in Adults in Holguín, Cuba (2004−2013). Medicc Rev. 2016[citado 6 sep 2019]; 18 (1-2). Disponible en: https://www.scielosp.org/pdf/medicc/2016.v18n1-2/28-33/en

  11. Carvalho Ribeiro de Sá L, Monteles Nascimento L, Medeiros Mascarenhas MD, Pacheco Rodrigues MT, Oliveira Gomes KR, de Macêdo Gonçalves Frota K. Factores asociados con el perfil lipídico de adolescentes. Rev Chilena Nutr. 2019 [citado 6 sep 2019]; 46(1): 32-38. Disponible en: http://dx.doi.org/10.4067/s0717-75182019000100032

  12. Al Duais MA, Al Awthan YS. Prevalence of dyslipidemia among students of a Yemeni University. J Taibah Univ Med Sci. 2019[citado 6 sep 2019]; 14(2): 163–171. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694883/pdf/main.pdf

  13. Elmaoğulları S, Tepe D, Uçaktürk SA, Kara FK, Demirel F. Prevalence of Dyslipidemia and Associated Factors in Obese Children and Adolescents. J Clin Res Pediatr Endocrinol. 2015[citado 6 sep 2019]; 7(3): 228–234. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677559/pdf/JCRPE-7-228.pdf

  14. Diéguez Martínez M, Miguel Soca P, Rodríguez Hernández R, López Báster J, Ponce de León D, Reyna Carralero J. Prevalence of hypertriglyceridemia and cardiovascular risk factors in students from the University of Medical Sciences. Holguin, 2014-2015. Medisur. 2018 [citado 6 sep 2019]; 16(1): 35-46. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2018000100007&lng=es

  15. Palacio Rojas M, Prieto C, Bermúdez V, Garicano C, Núñez Nava T, Martínez MS, et al. Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism. Version 2. F1000Res. 2017[citado 6 sep 2019]; 6: 2073. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171722/pdf/f1000research-6-17787.pdf

  16. Tada H, Kawashiri MA, Yamagishi M. Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. J Atheroscler Thromb. 2017[citado 6 sep 2019]; 24(5): 452–461. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429159/pdf/jat-24-452.pdf

  17. Jialal I, Singh G. Management of diabetic dyslipidemia: An update. World J Diabetes. 2019[citado 6 sep 2019]; 10(5):280-290. Disponible en: https://dx.doi.org/10.4239/wjd.v10.i5.280

  18. El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2019[citado 6 sep 2019]; 20(9). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539803/pdf/ijms-20-02215.pdf

  19. Reiner Ž. Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circ J. 2018[citado 6 sep 2019];48(12):1097-1119. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221868/

  20. Vázquez Jiménez JG, Roura Guiberna A, Jiménez Mena LR, Olivares Reyes JA. El papel de los ácidos grasos libres en la resistencia a la insulina. Gac Med México. 2017[citado 6 sep 2019];153(7):852-863. Disponible en: http://gacetamedicademexico.com/files/gmm_153_7_852-863.pdf

  21. Tagi VM, Giannini C, Chiarelli F. Insulin Resistance in Children. Front Endocrinol (Lausanne). 2019[citado 7 sep 2019]; 10: 342. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558106/pdf/fendo-10-00342.pdf

  22. Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. 2019[citado 6 sep 2019]; 20(5): 1190. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429491/pdf/ijms-20-01190.pdf

  23. Ruan h, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. 2016[citado 6 sep 2019]; 8(2): 101–109. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816150/pdf/mjw014.pdf

  24. Ide K, Koshizaka M, Tokuyama H, Tokuyama T, Ishikawa T, Maezawa Y, et al. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study. Lipids Health Dis. 2018[citado 6 sep 2019]; 17(1):51. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855932/pdf/12944_2018_Article_706.pdf

  25. Flisiak Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol. 2019[citado 6 sep 2019]; 5(1):11-21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431091/pdf/CEH-5-83152.pdf

  26. Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018[citado 6 sep 2019]; 25(9): 771–782. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143775/pdf/jat-25-771.pdf

  27. Wang Z, Wang D, Wang Y. Cigarette Smoking and Adipose Tissue: The Emerging Role in Progression of Atherosclerosis. Mediators Inflamm. 2017[citado 6 sep 2019]; 2017:3102737. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763059/pdf/MI2017-3102737.pdf

  28. Closs CI, Ruiz Diaz MA, Cafferata AM, Becú Villalobos D, Nogueira JP. Rol del enterocito en la dislipidemia de la diabetes mellitus tipo 2.Medicina (B Aires). 2018[citado 6 sep 2019]; 78(2):91-98. Disponible en: http://www.medicinabuenosaires.com/PMID/29659358.pdf

  29. Rygiel K. Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies. Curr Cardiol Rev. 2018[citado 6 sep 2019];14(1):67-76. Disponible en: https://doi.org/10.2174/1573403X14666180123165542

  30. Riggs KA, Rohatgi A. HDL and Reverse Cholesterol Transport Biomarkers. Methodist Debakey Cardiovasc J. 2019[citado 6 sep 2019]; 15 (1):39-46. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489608/pdf/i1947-6094-15-1-39.pdf

  31. Anderson TJ, Mancini GB, Genest J Jr, Grégoire J, Lonn EM, Hegele RA. The new dyslipidemia guidelines: what is the debate? Can J Cardiol. 2015[citado 6 sep 2019]; 31(5):605-612. Disponible en: https://doi.org/10.1016/j.cjca.2014.11.007

  32. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia in Korea. Korean J Intern Med. 2019[citado 6 sep 2019]; 34(5):1171. Disponible en: https://doi.org/10.3904/kjim.2019.188.e1

  33. Pedret A, Fernández Castillejo S, Valls RM, Catalán Ú, Rubió L, Romeu M, et al. Cardiovascular Benefits of Phenol‐Enriched Virgin Olive Oils: New Insights from the Virgin Olive Oil and HDL Functionality (VOHF) Study. Mol Nutr Food Res. 2018[citado 6 sep 2019]; 62 (16): 1800456. Disponible en: https://doi.org/10.1002/mnfr.201800456

  34. Miguel Soca PE, Cruz Torres W, González Ferrer J, Cardona Cáceres X, Cruz Lage LA, Hernández Tamayo M. Efectos beneficiosos de cambios en la dieta y ejercicios físicos en mujeres obesas con síndrome metabólico. Panorama. Cuba Salud. 2009 [citado 8 sep 2019];4(3). Disponible en: http://revpanorama.sld.cu/index.php/panorama/article/view/121

  35. Miguel Soca PE, Peña Pérez I, Niño Escofet S, Cruz Torres W, Niño Peña A, Ponce De León D. Ensayo clínico aleatorio: papel de la dieta y ejercicios físicos en mujeres con síndrome metabólico. Aten Prim. 2012[citado 6 sep 2019]; 44 (7): 387-393. Disponible en: https://doi.org/10.1016/j.aprim.2011.07.010

  36. Ochoa Expósito K, Rivas Estévez M, Miguel Soca PE, Batista Hernández A, Leyva Sicilia Y. Ensayo no aleatorizado: impacto de cambios en la dieta y ejercicios físicos en pacientes adultos con síndrome metabólico. CCM. 2015 [citado 6 sep 2019];19(3). Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/2156

  37. Wang Z, Wang D, Wang Y. Cigarette Smoking and Adipose Tissue: The Emerging Role in Progression of Atherosclerosis. Mediators Inflamm. 2017[citado 6 sep 2019]; 2017:3102737. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763059/pdf/MI2017-3102737.pdf

  38. Ida S, Kaneko R, Murata K. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019[citado 8 sep 2019]; 18(1): 38. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429757/pdf/12933_2019_Article_845.pdf

  39. Barbalho SM, Tofano RJ, Bueno de Oliveira M, Rodrigues Quesada K, Ricci Barion M, Akuri MC, et al. HDL-C and non-HDL-C levels are associated with anthropometric and biochemical parameters. J Vasc Bras. 2019 [citado 5 sep 2019]; 18: e20180109. Disponible en: http://dx.doi.org/10.1590/1677-5449.180109




2020     |     www.medigraphic.com